anti-PD-(L)1 drug
Nov 05, 2026
After KEYTRUDA: How PD-1 and PD-L1 Inhibitors Are Being Redesigned for a Post-Patent Era
Summary The PD-1 and PD-L1 inhibitors list now spans a dozen or more approved drugs. Clinical efficacy is broadly similar across them, so winners are decided by trial breadth, indication coverage, and convenience. Subcutaneous atezolizumab (2024), nivolumab (2024), and pembrolizumab (Keytruda Qlex, September...
Read More...
Sep 23, 2024
Roche’s TECENTRIQ HYBREZA: Setting New Standards as the First Subcutaneous Anti-PD-(L)1 Drug
Better late than never for FDA approval of the first subcutaneous PD-L1 inhibitor—Roche’s TECENTRIQ HYBREZA—after manufacturing delays disrupted the company’s initial launch plans last year. The FDA was originally set to decide on TECENTRIQ’s under-the-skin formulation in September, but Roche’s delivery technolo...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
